Variables | Drug used | |||||||
---|---|---|---|---|---|---|---|---|
Aflibercept | Bevacizumab | Ranibizumab | Ziv-aflibercept | |||||
n | % | n | % | n | % | n | % | |
Age | (n = 33) | (n = 32) | (n = 33) | (n = 33) | ||||
Mean ± SD | 77,7 ± 8,4 | 80,0 ± 6,9 | 77,3 ± 6,4 | 74,5 ± 7,8 | ||||
Median (Q1–Q3) | 78,0 (70,0–85,5) | 80,5 (75,3–86,0) | 78,0 (73,5–82,0) | 76,0 (67,5–80,5) | ||||
Mín–Máx | 60,0–90,0 | 63,0–90,0 | 63,0–88,0 | 59,0–87,0 | ||||
Sex | ||||||||
Male | 13 | 39,4 | 7 | 21,9 | 10 | 30,3 | 15 | 45,5 |
Female | 20 | 60,6 | 25 | 78,1 | 23 | 69,7 | 18 | 54,5 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Race | ||||||||
White | 29 | 87,9 | 24 | 75,0 | 27 | 81,8 | 30 | 90,9 |
Brown | 0 | 0,0 | 2 | 6,3 | 2 | 6,1 | 0 | 0,0 |
Black | 4 | 12,1 | 6 | 18,7 | 4 | 12,1 | 3 | 9,1 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Smoking | ||||||||
Yes | 8 | 24,2 | 10 | 31,3 | 12 | 36,4 | 12 | 32,1 |
No | 25 | 75,8 | 22 | 68,7 | 21 | 63,6 | 21 | 67,9 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Variables | Drug used | |||||||
---|---|---|---|---|---|---|---|---|
Aflibercept | Bevacizumab | Ranibizumab | Ziv-aflibercept | |||||
n | % | n | % | n | % | n | % | |
Hypercholesterolemia | ||||||||
Yes | 18 | 54,5 | 18 | 56,2 | 23 | 69,7 | 21 | 63,6 |
No | 15 | 45,5 | 14 | 43,8 | 10 | 30,3 | 12 | 36,4 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Hypertension | ||||||||
Yes | 31 | 93,9 | 28 | 87,5 | 30 | 90,9 | 31 | 93,9 |
No | 2 | 6,1 | 4 | 12,5 | 3 | 9,1 | 2 | 6,1 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Time of symptoms (months) | (n = 33) | (n = 32) | (n = 33) | (n = 33) | ||||
Mean ± SD | 15,7 ± 21,1 | 12,9 ± 12,4 | 23,2 ± 27,9 | 14,5 ± 17,3 | ||||
Median (Q1–Q3) | 6,0 (4,0–12,0) | 6,5 (4,3–21,0) | 12,0 (4,0–24,0) | 6,0 (3,0–18,0) | ||||
Mín–Máx | 1,0–96,0 | 3,0–48,0 | 3,0–108,0 | 2,0–60,0 | ||||
Previous treatment | ||||||||
Yes | 11 | 33,3 | 10 | 31,3 | 16 | 48,5 | 15 | 39,7 |
No | 22 | 66,7 | 22 | 68,7 | 17 | 51,5 | 18 | 60,3 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Variables | Drug used | |||||||
---|---|---|---|---|---|---|---|---|
Aflibercept | Bevacizumab | Ranibizumab | Ziv-aflibercept | |||||
n | % | n | % | n | % | n | % | |
Baseline BCVA | ||||||||
0,30 (20/40) | 1 | 3,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
0,48 (20/60) | 0 | 0,0 | 0 | 0,0 | 1 | 3,0 | 1 | 3,0 |
0,54 (20/70) | 7 | 21,2 | 7 | 21,9 | 2 | 6,1 | 5 | 15,2 |
0,60 (20/80) | 2 | 6,1 | 1 | 3,1 | 0 | 0,0 | 1 | 3,0 |
0,70 (20/100) | 9 | 27,3 | 7 | 21,9 | 9 | 27,3 | 4 | 12,1 |
1,00 (20/200) | 10 | 30,3 | 10 | 31,2 | 7 | 21,2 | 8 | 24,3 |
1,18 (20/300) | 0 | 0,0 | 0 | 0,0 | 1 | 3,0 | 0 | 0,0 |
1,30 (20/400) | 4 | 12,1 | 7 | 21,9 | 13 | 39,4 | 14 | 42,4 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Baseline IOP | ||||||||
9 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 2 | 6,1 |
10 | 2 | 6,1 | 5 | 15,6 | 1 | 3,0 | 0 | 0,0 |
11 | 6 | 18,2 | 9 | 28,1 | 5 | 15,2 | 9 | 27,3 |
12 | 4 | 12,1 | 4 | 12,5 | 5 | 15,2 | 5 | 15,2 |
13 | 9 | 27,3 | 5 | 15,6 | 6 | 18,2 | 5 | 15,2 |
14 | 3 | 9,1 | 2 | 6,3 | 6 | 18,2 | 1 | 3,0 |
15 | 1 | 3,0 | 2 | 6,3 | 6 | 18,2 | 1 | 3,0 |
16 | 3 | 9,1 | 5 | 15,6 | 3 | 9,1 | 6 | 18,2 |
17 | 4 | 12,1 | 0 | 0,0 | 0 | 0,0 | 3 | 9,1 |
18 | 1 | 3,0 | 0 | 0,0 | 0 | 0,0 | 1 | 3,0 |
19 | 0 | 0,0 | 0 | 0,0 | 1 | 3,0 | 0 | 0,0 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Variables | Drug used | |||||||
---|---|---|---|---|---|---|---|---|
Aflibercept | Bevacizumab | Ranibizumab | Ziv-aflibercept | |||||
n | % | n | % | n | % | n | % | |
Baseline IOP | (n = 33) | (n = 32) | (n = 33) | (n = 33) | ||||
Mean ± SD | 13,4 ± 2,3 | 12,5 ± 2,1 | 13,5 ± 1,9 | 13,2 ± 2,5 | ||||
Median (Q1–Q3) | 13,0 (11,5–15,5) | 12,0 (11,0–14,0) | 13,0 (12,0–15,0) | 13,0 (11,0–16,0) | ||||
Mín–Máx | 10,0–18,0 | 10,0–16,0 | 10,0–19,0 | 9,0–18,0 | ||||
Baseline CTR | (n = 33) | (n = 32) | (n = 33) | (n = 33) | ||||
Mean ± SD | 432 ± 73 | 470 ± 81 | 449 ± 73 | 469 ± 75 | ||||
Median (Q1–Q3) | 413 (383–490) | 477 (397–536) | 450 (393–493) | 464 (400–526) | ||||
Mín–Máx | 285–587 | 337–631 | 342–631 | 332–610 | ||||
Baseline IRF | ||||||||
Yes | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
No | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |
Baseline SRF | ||||||||
Yes | 33 | 100,0 | 30 | 93,7 | 31 | 93,9 | 33 | 100,0 |
No | 0 | 0,0 | 2 | 6,3 | 2 | 6,1 | 0 | 0,0 |
TOTAL | 33 | 100,0 | 32 | 100,0 | 33 | 100,0 | 33 | 100,0 |